Project Grant HT94252410306
Award Date
5/1/24
Completion Date
4/30/26
Dollars Obligated
$1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
The Trustees of Columbia University in New York City will receive $809,262 from the Department of the Army Medical Command under a Project Grant award to support preclinical characterization of AZVIII-7-18, a novel Paullone derivative for the treatment of ALS. The funding period is from July 1, 2022 to June 30, 2024. The award is being made through the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research aimed at...
The Trustees of Columbia University in the City of New York will receive $1,619,986 from the Department of the Army Medical Command under a two-year Project Grant award to support preclinical characterization of Prosetin, a brain-penetrant MAP4K inhibitor for treating ALS. The grant was awarded on May 1, 2021 under the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care...
The Department of the Army Medical Command awarded a $879,721 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to The Trustees of Columbia University in the City of New York. The grant, with a performance period from April 1, 2025 to March 31, 2027, will fund the evaluation of small molecule ferroptosis inhibitors in a GPX4 amyotrophic lateral sclerosis (ALS) model. This research aims to transform healthcare for military service members and the public by...
The Trustees of Columbia University in New York City will receive $486,000 from the Defense Health Agency through March 2024 to analyze the adaptive and innate immune response in patients with amyotrophic lateral sclerosis (ALS) who have been treated with antisense oligonucleotides. This Project Grant was awarded on April 1, 2021 under the Military Medical Research and Development program (CFDA 12.420). The Defense Health Agency's Military Medical Research and Development program aims to...
The Trustees of Columbia University in New York City will receive $567,000 from the Department of the Army Medical Command under a three-year Project Grant award to identify epigenetic vulnerabilities in peripheral T-cell lymphomas. The grant period runs from September 1, 2022 through August 31, 2025. The funding supports research conducted under the Military Medical Research and Development program (CFDA 12.420), which aims to transform military and public health through innovative biomedical...
The Trustees of Columbia University in the City of New York, doing business as Health Sciences Division, was awarded a $656,272 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research aimed at optimizing PD-1 immunotherapy through increased T cell regeneration and reduced antigen load. This 2-year project will be conducted in New York, NY from September 1, 2023 to August 31, 2025. The Military Medical...
The Trustees of Columbia University in the City of New York (Columbia University) was awarded a $658,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2026 targeting inflammatory signals as therapeutic strategies for peripheral T-cell lymphoma. Through this award, Columbia University will investigate medical solutions for lymphoma, a type of cancer...
The University of Massachusetts Medical School has been awarded a $987,615 federal Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, which runs from September 30, 2024 to September 29, 2026, supports the "Development of Chimeric Antigen Receptor T Regulatory Cells (CAR Tregs) for the Treatment of Amyotrophic Lateral Sclerosis." This project aims to advance research into new therapeutic approaches for...
The Trustees of Columbia University in the City of New York received a $1.9 million Project Grant award from the Department of the Army Medical Command on August 15, 2022 to fund research on Protein Transduction Therapy for Acute Respiratory Distress Syndrome (ARDS). The research will be conducted through August 14, 2025 in New York, NY under the Military Medical Research and Development program (CFDA 12.420). This program supports basic, applied, and advanced biomedical research with the...
The Department of the Army Medical Command awarded Dartmouth College a $962,758 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to develop TDP43-specific human CAR T-cells as a therapy for amyotrophic lateral sclerosis (ALS). The grant, with a performance period from July 1, 2024 to June 30, 2026, will support Dartmouth's research into manufacturing and evaluating this novel CAR T-cell immunotherapy for treating ALS, a devastating neurodegenerative disease...